Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Amsterdam
Clinical trial register · Netherlands

Clinical Trials in Amsterdam, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Netherlands and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3174 matching records held by the registry are in this view. Synced 16 Nov 2026, 03:18 UTC
3174
Studies in scope
all four open statuses
1791
Recruiting now
open to new participants
602
Lead sponsors
across recruiting studies
Top sites
Amsterdam 58 Rotterdam 36 Groningen 20 Maastricht 19 Nijmegen 17

Trials with a site in Amsterdam

58 of 3174 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Netherlands
Start
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Amsterdam, Heerlen, Nieuwegein
2026-06-11
Recruiting
AstraZeneca
Phase 3
670
Amsterdam, Nijmegen
2026-05-04
Recruiting
AstraZeneca
Phase 3
2,130
Amsterdam, Groningen, Rotterdam, Tilburg
2026-02-03
Recruiting
AstraZeneca
Phase 3
1,100
Amsterdam, Groningen, Maastricht, Utrecht
2025-12-04
Recruiting
AstraZeneca
Phase 1
23
Amsterdam, Groningen, Rotterdam, Utrecht
2025-12-01
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Amsterdam, Groningen, Leiden
2025-11-24
Recruiting
AstraZeneca
Phase 2
435
Amsterdam, Rotterdam, Zutphens
2025-11-06
Recruiting
AstraZeneca
Phase 3
800
Amsterdam, Maastricht
2025-08-01
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
AstraZeneca
Phase 3
473
Amsterdam, Roosendaal, Rotterdam, Utrecht
2025-06-10
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
AstraZeneca
Phase 2
150
Amsterdam, Nijmegen, Rotterdam
2025-05-15
Recruiting
AstraZeneca
Phase 3
1,220
Amsterdam, Groningen, Maastricht, Rotterdam, Utrecht
2025-05-06
Recruiting
AstraZeneca
Phase 1
72
Amsterdam, Leiden
2025-05-01
Recruiting
AstraZeneca
Phase 3
11,300
's-Hertogenbosch, Almelo, Amsterdam, Born, Deventer, Ede, Enschede, Haarlem
2025-03-14
Active, closed
AstraZeneca
Phase 2
82
Amsterdam, Maastricht, Zwolle
2025-03-12
Recruiting
AstraZeneca
Phase 3
5,000
Amersfoort, Amsterdam, Dordrecht, Groningen, Hilversum, Leiden, Maastricht, Nieuwegein
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Amsterdam, Arnhem, Leiden
2025-03-01
Active, closed
AstraZeneca
Phase 2
24
Amsterdam, Nijmegen
2024-12-11
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Amsterdam
2024-08-28
Recruiting
AstraZeneca
Phase 3
3,850
Amsterdam, Arnhem, Emmen, Goes, Hardenberg, Leeuwarden
2024-04-12
Recruiting
AstraZeneca
Phase 1/2
334
Amsterdam
2024-01-18
Active, closed
AstraZeneca
Phase 3
1,898
Amsterdam, Hilversum, Nijmegen
2023-11-21
Active, closed
AstraZeneca
Phase 3
863
Amsterdam, Eindhoven, Rotterdam
2023-11-09
Active, closed
AstraZeneca
Phase 3
895
Amsterdam, Nieuwegein, Tilburg
2023-10-24
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
392
Amsterdam, Groningen, Rotterdam
2023-07-11
Active, closed
AstraZeneca
Phase 3
368
Amsterdam, Nijmegen, Rotterdam
2022-11-10
Active, closed
AstraZeneca
Phase 3
363
Amsterdam
2022-02-15
Active, closed
AstraZeneca
Phase 3
148
Amsterdam, Arnhem, Rotterdam
2021-10-28
Recruiting
AstraZeneca
Phase 1/2
460
Amsterdam
2021-10-18
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 1/2
136
Amsterdam
2021-09-28
Recruiting
AstraZeneca
Phase 1
304
Amsterdam
2021-03-09
Active, closed
AstraZeneca
Phase 3
957
Amsterdam, Eindhoven, Rotterdam
2020-11-17
Active, closed
AstraZeneca
Phase 3
370
Amsterdam, Maastricht, Nijmegen
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
Amsterdam, Delft, Groningen
2020-08-18
Active, closed
AstraZeneca
Phase 3
866
Amsterdam, Breda, Hengelo, Leeuwarden, Rotterdam, Sittard-Geleen
2020-07-24
Active, closed
AstraZeneca
Phase 3
1,012
Amsterdam, Hilversum, Roosendaal, The Hague, Tilburg, Utrecht
2020-07-13
Active, closed
AstraZeneca
Phase 2
247
Amsterdam, Maastricht, Nijmegen, Rotterdam
2019-06-25
Active, closed
AstraZeneca
Phase 3
1,063
Amsterdam, Breda, Rotterdam
2018-11-16
Active, closed
AstraZeneca
Phase 3
730
's-Hertogenbosch, Amsterdam, Groningen, Harderwijk, Hengelo
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,018
Amsterdam, Breda, Utrecht
2018-05-14
Active, closed
AstraZeneca
Phase 3
987
Amsterdam, Arnhem, Groningen, Hengelo, Maastricht, Rotterdam
2017-03-27
Active, closed
AstraZeneca
Phase 1/2
264
Amsterdam, Maastricht, Nijmegen, Rotterdam, Utrecht
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,126
Amsterdam, Breda, Enschede, Groningen, Leiden, Maastricht, Nijmegen
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Amsterdam, Arnhem, Hoofddorp, Zwolle
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
's-Hertogenbosch, Amsterdam, Arnhem, Breda, Groningen, Maastricht, Rotterdam
2015-07-21
Active, closed
AstraZeneca
Phase 3
1,837
Amsterdam, Breda, Geleen, Leiden, Maastricht, Rotterdam, Zaandam
2014-04-22
Active, closed
AstraZeneca
Phase 3
510
's-Hertogenbosch, Amsterdam, Bergen op Zoom, Maastricht
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Amsterdam, Maastricht, Nijmegen, Rotterdam
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Amsterdam, Maastricht
2013-08-26
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Dutch investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 November 2026. https://priyalifescience.com/clinical-trials-netherlands/city/amsterdam

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Netherlands and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,174 studies in total at the last sync on 16 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Amsterdam that also match the filters currently applied.

How many clinical trials are recruiting in Amsterdam?

24 of the 58 studies on this page are recruiting new participants as of the 16 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 34 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Amsterdam), 58 studies
PhaseStudiesRecruitingShare
Phase 3371263.8%
Phase 211419%
Phase 1/27512.1%
Phase 1335.2%

Most active sponsors

Lead sponsors with the most studies (Amsterdam)
Lead sponsorStudiesRecruiting
AstraZeneca5824
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.